Characterization of the Mechanisms of Resistance to Azacitidine

Centre Hospitalier Universitaire de Nice

Status: Unknown

Conditions: Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

Study type: Observational

Funder types: Other

Identifiers

NCT01210274

10-PP-10

Details and patient eligibility

About

Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has been mainly achieved through a rigorous empirical and clinical research, but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized. The primary mode of action of Azacytidine is through DNA demethylation, and integration in to mRNA that favor traduction inhibition. The impact of this molecule on various cell death programs involved in the elimination of leukemic cells : apoptosis and autophagy is currently poorly known.

The research program and clinical studies we proposed focus on two major aspects:

• Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of apoptosis versus autophagy.

• Secondary Objective: Reversion of Azacytidine resistance using different drugs targeting apoptosis and/or autophagy. Our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• High Risk or Intermediate 2 MDS (IPSS)
• AML-MD (WHO classification)
• Treatment with minimum three to six cycles of Azacitidine
• Informed consent form signed

Exclusion criteria

• Treatment with others chemotherapies alone or in association